Anti-SARS-CoV-2 (B.1.351) Neutralizing Antibody Titer Serologic Assay Kit (Spike RBD)

This assay kit is used to measure the levels of Anti-SARS-CoV-2 neutralizing antibody through a competitive ELISA. The microplate in the kit has been pre-coated with Human ACE2 protein. First serum samples, Positive control, Negative Control are added to the wells followed by addition of HRP-SARS-CoV-2 Spike RBD. After incubation, the wells are washed and substrate is added to the wells. The reaction is terminated by the addition of stop solution and the intensity of color is measured at 450 nm. The presence of neutralizing antibodies in samples will compete with ACE2 for HRP-SARS-CoV-2 Spike RBD binding. The intensity of assay signal decrease proportionally to the presence of Anti-SARS-CoV-2 neutralizing antibody.

Multiple variants of SARS-CoV-2 are circulating globally and posting new challenges to human health. As concerns over the potential impacts of the variants grow, people ask if one possesses protective neutralizing antibodies (NAbs) against the variants after receiving the currently available vaccines; and if the NAb therapeutic agents are equally effective to treat the mutant infection as the wild type. To facilitate the mutant-related research, drug trials and vaccine assessments, a high-throughput assay to measure neutralizing antibodies against the mutants is in urgent need.

2-8?